Rotarix effective in severe diarrhea in developing world

New data on rotavirus vaccine from Mexico and Africa show lifesaving impact in the developing world — Evidence informed WHO recommendation that all countries introduce rotavirus vaccine – Rotavirus is the leading cause of severe, acute gastroenteritis among infants and young children throughout the world and is responsible for an estimated 527,000 deaths among children under five each year.

Climate change a biggest health threat of 21st century

Climate change is the biggest health threat of the 21st Century, researchers claim. – A major report on managing the health effects of climate change, launched jointly by The Lancet and UCL (University College London) today, says that climate change is the biggest global health threat of the 21st Century.

GSK’s new vaccine Rotarix to prevent gastroenteritis by rotavirus

The Food and Drug Administration has approved the GlaxoSmithKline (NYSE:GSK) vaccine Rotarix for use in infants. – The U.S. Food and Drug Administration announced the approval of Rotarix, the second oral U.S. licensed vaccine for the prevention of rotavirus, an infection that causes gastroenteritis (vomiting and diarrhea) in infants and children. Rotarix is a liquid and given in a two-dose series to infants from 6 to 24 weeks of age.